Obsidian Therapeutics has reported positive top-line data from a Phase I clinical trial of its cell therapy candidate, OBX-115, to treat metastatic melanoma.
The first-in-human trial that is underway is designed to analyse the efficacy and safety of OBX-115 in patients with melanoma that has relapsed and/or is refractory to previous treatment with an immune checkpoint inhibitor (ICI).
Go deeper with GlobalData
An objective response rate (ORR) of 50%, with 33% complete responses, was reported at a median follow-up period of 18 weeks.
Disease control rate in the trial was 100%, with responses intensifying over time.
No dose-limiting toxicities were reported in the trial, and the treatment-emergent adverse event profile was in line with that of lymphodepletion.
A tumour-infiltrating lymphocyte (TIL) cell therapy with pharmacologically regulatable membrane-bound IL15, OBX-115 has the potential to become a therapeutic option for melanoma and other solid tumours.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataObsidian Therapeutics chief development officer Parameswaran Hari said: “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy.
“These initial topline results support the promise for OBX-115 to drive responses in this heavily pre-treated patient population and facilitate the expansion of TIL cell therapy in melanoma to a broad group of patients, without the need for IL2 [interleukin-2].”
In another development, the company enrolled the first subject in a multicentre Phase I/II clinical trial of OBX-115 in patients with advanced or metastatic melanoma who are resistant to ICI therapy.
Obsidian Therapeutics CEO Madan Jagasia said: “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy, without the need for IL2.
“Furthermore, the emerging profile of OBX-115 indicates it will allow expansion of TIL cell therapy into a broad patient population, including those who may not be able to tolerate IL2 or choose not to receive it.”
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
